Enliven Therapeutics, Inc. Common Stock
ELVNEnliven Therapeutics, Inc. (ELVN) is a biotechnology company focused on developing targeted small molecule medicines for cancer and genetic diseases. The firm specializes in utilizing precision medicine approaches to create therapies that modulate disease-related pathways, aiming to improve treatment outcomes and reduce side effects.
Company News
OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics (ELVN) for approximately $39 million on June 22, 2026, representing 11.60% of its holdings. Despite the partial exit following a 130% stock rally, OrbiMed retains over 6.5 million shares, signaling continued confidence. Enliven, a clinical-stage biotech focused on cancer therapies, has ...
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a ...
Enliven Therapeutics' Chief Medical Officer Helen Collins sold 5,000 shares worth approximately $199,000 on May 18, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Collins retains over 150,000 shares in the company, suggesting confidence in the biotech firm. The sale occurred during a period of strong stock performa...
Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.
Enliven Therapeutics (ELVN) is a good choice for trend investors due to its recent price increase, positive earnings estimate revisions, and strong fundamentals, making it a Zacks Rank #2 (Buy) stock.
